Drug General Information |
Drug ID |
D0V0PR
|
Former ID |
DNC010056
|
Drug Name |
4-(2-(phenoxymethyl)phenyl)piperidine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H21NO
|
Canonical SMILES |
C1CNCCC1C2=CC=CC=C2COC3=CC=CC=C3
|
InChI |
1S/C18H21NO/c1-2-7-17(8-3-1)20-14-16-6-4-5-9-18(16)15-10-12-19-13-11-15/h1-9,15,19H,10-14H2
|
InChIKey |
SYLMRMITUMFBTA-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholismhsa04726:Serotonergic synapse
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesisP00001:Adrenaline and noradrenaline biosynthesis
|
Parkinson disease
|
Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
|
5HT2 type receptor mediated signaling pathway
|
5HT3 type receptor mediated signaling pathway
|
5HT4 type receptor mediated signaling pathway
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
WikiPathways
|
Monoamine Transport
|
NRF2 pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
|
Dopaminergic Neurogenesis
|
Parkinsons Disease Pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport
|
SIDS Susceptibility Pathways
|
Synaptic Vesicle Pathway
|
Serotonin Transporter Activity
|
References |
REF 1 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. |